Pont Mestres & Asociados
1
3M
1
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Pont Mestres & Asociados, startups are often financed by VenturCap, Uninvest, Caixa Capital Risc. The meaningful sponsors for the fund in investment in the same round are VenturCap, Uninvest, Caixa Capital Risc. In the next rounds fund is usually obtained by Caixa Capital Risc, Asclepios Biosearch, VenturCap.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Genmedica Therapeutics, Genmedica Therapeutics. Among the most popular fund investment industries, there are Biotechnology, Pharmaceutical.
The high activity for fund was in 2011. The fund is generally included in less than 2 deals every year. Deals in the range of 1 - 5 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Investments by industry
- Medical Device (1)
- Biotechnology (1)
- Pharmaceutical (1)
- Investments by region
-
- Spain (1)
- Peak activity year
- 2011
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.